ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease.
ABIVAX leverages three technology platforms for drug discovery:
- an anti-viral platform,
- an immune enhancement platform,
- a polyclonal antibody platform.
ABX464, its most advanced compound, is currently in Phase II clinical trials and is a first-in-class oral small anti-viral molecule which blocks HIV replication through a unique mechanism of action. In addition, ABIVAX is advancing multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer, and several of these compounds are planned to enter clinical development within the next 18 months.